Cingulate

Cingulate EBITDA per Share

The EBITDA per Share of Cingulate (CING) as of Nov 21, 2026 is -3.88 USD. In the previous year, EBITDA per Share was -4.60 USD — a change of -15.56% (higher).

EBITDA per Share

-3.88USD

YoY

-15.56%

Last updated:

EBITDA per Share of Cingulate is 2025 -3.88 USD. EBITDA per Share of Cingulate was 2024 -4.60 USD. It decreases by -15.56% higher compared to the previous year.

The Cingulate EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-2.14 USD
Jan 1, 2020
-5.01 USD
Jan 1, 2021
-20.10 USD
Jan 1, 2022
-12.38 USD
Jan 1, 2023
-233.98 USD
Jan 1, 2024
-4.60 USD
Jan 1, 2025
-3.88 USD
The Cingulate EBITDA per Share history
YEAREBITDA per ShareYoY
-3.88USD-15.56%
-4.60USD-98.03%
-233.98USD+1,790.01%
-12.38USD-38.42%
-20.10USD+301.21%
-5.01USD+133.64%
-2.14USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

EBITDA per Share of Cingulate is -3.88 USD in 2025.

EBITDA per Share of Cingulate changed from -4.60 USD to -3.88 USD, representing a -15.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Cingulate since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cingulate

All Key Metrics — Cingulate